Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Activity of SM2275 in Patients With Advanced Solid Tumors

NCT07750132 is registered in ClinicalTrials.gov with Beijing StarMab Biomed Technology Ltd as lead sponsor.

NCT NCT07750132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07750132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Activity of SM2275 in Patients With Advanced Solid Tumors
Lead sponsor
Beijing StarMab Biomed Technology Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 20, 2026
Completion date
February 2, 2029
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors